Exact Sciences Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences or view top-rated stocks.

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Exact Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Exact Sciences.

Exact Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings data on Monday, February, 15th. The medical research company reported ($2.79) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $2.60. Exact Sciences had a negative trailing twelve-month return on equity of 11.71% and a negative net margin of 25.27%.
View Exact Sciences' earnings history.

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EXAS shares have increased by 137.4% and is now trading at $137.25.
View which stocks have been most impacted by COVID-19.

15 Wall Street analysts have issued 12 month target prices for Exact Sciences' shares. Their forecasts range from $70.00 to $226.00. On average, they expect Exact Sciences' stock price to reach $145.31 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for Exact Sciences or view top-rated stocks among Wall Street analysts.

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Exact Sciences include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS).
View all of EXAS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Exact Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (2.12%), Sumitomo Mitsui Trust Holdings Inc. (1.22%), Zevenbergen Capital Investments LLC (1.21%), Nikko Asset Management Americas Inc. (0.88%), Frontier Capital Management Co. LLC (0.77%) and Baillie Gifford & Co. (0.76%). Company insiders that own Exact Sciences stock include G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Primecap Management Co. CA, Zevenbergen Capital Investments LLC, Frontier Capital Management Co. LLC, Factory Mutual Insurance Co., Nuveen Asset Management LLC, C WorldWide Group Holding A S, and Handelsbanken Fonder AB. Company insiders that have sold Exact Sciences company stock in the last year include Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Sarah Condella, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences or view top insider-selling stocks.

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Renaissance Technologies LLC, Avidity Partners Management LP, Artisan Partners Limited Partnership, Columbus Circle Investors, Victory Capital Management Inc., and Baillie Gifford & Co..
View insider buying and selling activity for Exact Sciences or or view top insider-buying stocks.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXAS stock can currently be purchased for approximately $137.25.

Exact Sciences has a market capitalization of $23.21 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

Exact Sciences employs 4,800 workers across the globe.

Exact Sciences was founded in 1995.

The official website for Exact Sciences is www.exactsciences.com.

Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815 or via email at [email protected]